anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The Hospital Frailty Risk Score (HFRS) is a tool for quantifying patient frailty using International Classification of Diseases, Tenth Revision codes. This study aimed to determine the utility of the HFRS in predicting surgical outcomes after resection of glioblastoma (GBM) and compare its prognostic ability with other validated indices such as American Society of Anesthesiologists score and Charlson Comorbidity Index.
METHODS: A retrospective analysis was conducted using a GBM patient database (2017-2019) at a single institution. HFRS was calculated using International Classification of Diseases, Tenth Revision codes. Bivariate logistic regression was used to model prognostic ability of each frailty index, and model discrimination was assessed using area under the receiver operating characteristic curve. Multivariate linear and logistic regression models were used to assess for significant associations between HFRS and continuous and binary postoperative outcomes, respectively.
RESULTS: The study included 263 patients with GBM. The HFRS had a significantly greater area under the receiver operating characteristic curve compared with American Society of Anesthesiologists score (P = 0.016) and Charlson Comorbidity Index (P = 0.037) for predicting 30-day readmission. On multivariate analysis, the HFRS was significantly and independently associated with hospital length of stay (P = 0.0038), nonroutine discharge (P = 0.018), and 30-day readmission (P = 0.0051).
CONCLUSIONS: The HFRS has utility in predicting postoperative outcomes for patients with GBM and more effectively predicts 30-day readmission than other frailty indices. The HFRS may be used as a tool for optimizing clinical decision making to reduce adverse postoperative outcomes in patients with GBM.
The invention provides esomeprazole enteric-coated tablets. The esomeprazole enteric-coated tablets comprise esomeprazole pellets, a filling agent, a disintegrating agent, a bonding agent, a lubricating agent and a coating material. The esomeprazole enteric-coated tablets are prepared through mixed tabletting; the esomeprazole pellets are prepared with a multilayer insulation blocking method, have good pressing ability and high acid resistance and are not easily damaged in the tableting process, and accordingly, the acid resistance cannot be reduced. The mixing uniformity is improved by optimizing the pellets, auxiliary materials and the mixing method, and the layering phenomenon in the tabletting process is reduced by optimizing the tabletting method. The esomeprazole enteric-coated tablets can be rapidly disintegrated and dispersed in water to form a suspension, accordingly, distribution of a drug in the gastrointestinal tract is facilitated, the drug bioavailability is improved, and the esomeprazole enteric-coated tablets are suitable for being taken by patients suffering from dysphagia. The problems of inconvenience in carrying of a dry suspension and inaccurate dosage are solved, dispersion media used in the preparation process are purified water, and residues of an organic solvent are avoided.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: claimed is pharmaceutical composition for treating psoriasis, which includes, at least, one excipient and active agents counted per total composition weight: clobetasol propionate: 0.05-5%, minoxydyl: 0.05-7% and 11-alfa-hydroxyprogesteron: 0.05-12%. Composition can also include other excipients, vitamins and/or mineral compounds. It is demonstrated: 11-alfa-hydroxyprogesteron reduces grease-secretion on affected region, which increases action of other active agents. Efficiency of composition is manifested 2-4 days after beginning of treatment, it does not change skin colour, side effects are manifested in light degree. ^ EFFECT: composition retards accelerated growth of skin cells, as well as suppresses development of other abnormal phenomena developing in case of psoriasis vulgaris. ^ 15 cl, 2 ex
<P>PROBLEM TO BE SOLVED: To provide a hair dye which can evenly dye hair, gives little damage to the hair at dyeing, imparts gloss, resilience, etc. to the dyed hair, makes the dyed hair easier to comb and is excellent in shampoo resistance after dyeing.  <P>SOLUTION: The hair dye contains a silylated peptide-silane compound copolymer composition having a viscosity of 500-20,000 mPas at 20°C when the solid concentration is 70%. The copolymer composition is obtained by subjecting a silylated peptide having two or more hydroxyl groups directly bonded to a silicon atom and a silane compound generating two or more hydroxyl groups directly bonded to a silicon atom to a polycondensation through hydrolysis and subsequently reacting the product with a silane compound generating a hydroxyl group directly bonded to a silicon atom through hydrolysis. Preferably, the hair dye contains 0.05-10 mass% of the copolymer composition.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Kidney stones result from abnormal biomineralization, although the mechanism behind their formation remains unclear. Annexin A6 (AnxA6), a calcium-dependent lipid-binding protein, is associated with several mineralization-related diseases, but its role in kidney stones is unknown. This study aimed to explore the role and mechanism of AnxA6 in calcium oxalate (CaOx) kidney stones. An in vitro model in which renal tubular epithelial cells (RTECs) were treated with 1 mmol/L oxalate was established, and AnxA6 protein and mRNA expression were examined. Genetic engineering, drug intervention, and biochemical assays were used to investigate the role of AnxA6. The results revealed that AnxA6 was significantly overexpressed in the CaOx model. AnxA6 knockdown in RTECs reduced oxalate-induced oxidative stress, ROS accumulation, and mitochondrial damage, whereas AnxA6 overexpression exacerbated these effects. Blocking ryanodine receptor-mediated calcium release reversed AnxA6-induced oxidative damage. Additionally, AnxA6 increased oxalate adhesion to RTECs by binding to oxalate. In conclusion, AnxA6 contributes to CaOx kidney stone formation by promoting both oxidative stress via calcium release and crystal-cell adhesion by binding to oxalate. This study offers new insight into CaOx kidney stone formation.
Post-COVID Syndrome has emerged as a significant public health concern worldwide with increasing evidence to suggest that individuals who have had an acute COVID-19 infection report lingering memory and attention difficulties, even in individuals who have fully recovered and no longer experiencing symptoms of COVID-19. The present study sought to investigate the profile of objective and subjective cognitive difficulties in people who have Post-COVID Syndrome, people who have fully recovered from an acute COVID infection and people who have never had COVID-19. We further sought to explore the extent to which self-reported fatigue and stress are related to subjective and objective cognitive difficulties. 162 participants including 50 people living with Post-COVID Syndrome, 59 people who have had COVID-19 but have fully recovered and 53 people who have never experienced symptoms of COVID-19 and had never tested positive for COVID-19 were recruited from Academic Prolific to complete a series of online questionnaires and neurocognitive tasks. Subjective cognitive function was measured using the Cognitive Failures Questionnaire and objective cognitive function was measured using the Cognitron cognitive test battery. We found that objective and subjective measures of cognitive function were not significantly related, suggesting that self-reports of "brain fog" are not reflecting objectively measured cognitive dysfunction. A MANOVA revealed that subjective cognitive deficits were driven by heightened perceived stress and fatigue and not significantly related to COVID-19 status. Objective cognitive function, however, was significantly related to perceived stress and COVID status whereby we observed significant objective cognitive deficits in people who have been exposed to an acute COVID-19 infection regardless of whether they had Post-COVID Syndrome or had fully recovered, as compared to people who had never had COVID-19. This suggests that an acute infection can have long term effects on cognitive function, even without persistent COVID-19 symptoms. Encouragingly, objective cognitive function was significantly associated with time since initial infection showing that cognitive deficits improved over time for people who had recovered from COVID-19. However, we did not observe the same improvement in individuals with Post-COVID Syndrome and observed that cognitive dysfunction was significantly related to the number of neurological symptoms presently experienced. These results add to the accumulating literature that COVID-19 is associated with significant cognitive difficulties following a COVID-19 infection, which appear to improve over time for those who have recovered from COVID-19 yet persist in people living with Post-COVID Syndrome.
PURPOSE: A gene delivery system containing renal cell-specific peptides and polyester amine polymers is provided to effectively deliver HGF gene to a target site and to suppress fibrosis. CONSTITUTION: A gene delivery system contains renal cell-specific peptides and polyester amine polymers. The renal cell-specific peptide is HOOC-ELRGDRAHW-NH_2. The polyester amine polymer is a copolymer of polyethylenimine and glycerol dimethacrylate. The delivery system is prepared by amide bond of a carboxyl group of rental cell-specific peptides and an amine group of polyester amine polymers. A HGF gene contains a base of sequence number 1. A composition for preventing or treating rental fibrosis contains a gene delivery complex.
We enroll adults older than 18 years with chronic lower GI symptoms for more than 1 month and are scheduled for a colonoscopy. The lower GI symptoms consist of any of the followings; lower abdominal pain, constipation, diarrhea, rectal bleeding, change in stool caliber, and abdominal bloating.
SARS-CoV-2 infection is considered as a multi-organ disease, and several studies highlighted the relevance of the virus infection in the induction of vascular injury and tissue morphological alterations, including placenta. In this study, immunohistochemical analyses were carried out on placenta samples derived from women with COVID-19 infection at delivery (SARS-CoV-2 PCR+) or women healed from a COVID-19 infection (SARS-CoV-2 negative at delivery, SARS-CoV-2 PCR-) or women who gave birth before 2019 (Control). Angiotensin Converting Enzyme 2 (ACE2) receptor, Cluster of differentiation 147 (CD147), endothelial CD34 marker, Vascular Endothelial Growth Factor (VEGF) and total Microtubule-associated protein 1 Light Chain 3B marker (LC3B) were investigated in parallel with SPIKE protein by standard IHC. Multiplexed Immunohistochemical Consecutive Staining on Single Slide (MICSSS) was used to examine antigen co-expression in the same specimen. SPIKE protein was detected in villi and decidua from women with ongoing infection, with no significant differences in SPIKE staining between both biopsy sites. VEGF was significantly increased in SARS-CoV-2 PCR + biopsies compared to control and SARS-CoV-2 PCR- samples, and MICSSS method showed the co-localization of SPIKE with VEGF and CD34. The induction of autophagy, as suggested by the LC3B increase in SARS-CoV-2 PCR + biopsies and the co-expression of LC3B with SPIKE protein, may explain one of the different mechanisms by which placenta may react to infection. These data could provide important information on the impact that SARS-CoV-2 may have on the placenta and mother-to-fetus transmission.
1,237,121. Dried embryonic product. A. SAMY. 30 April, 1969 [8 Feb., 1968], No. 6192/68. Addition to 1,059,230. Heading A2D. [Also in Division A5] An embryonic product is produced by removing the embryo in its membraneous sac from an animal prior to the development of the embryo to the foetal stage, sterilizing the embryo in the membraneous sac, extruding the embryonic content and freeze-drying the content. The embryo in its sac, after removal from an animal, may be treated with a solvent, for example alcohol, the solution so formed filtered and freeze-dried. The process is particularly applicable to the treatment of embryos of cows, mares, and sows.
The invention relates to a recombinant insulin secretion promoter fusion protein. A polypeptide zone of the recombinant insulin secretion promoter fusion protein comprises a human serum albumin and an insulin secretion promoter. The insulin secretion promoter in a form of one or more monomers is connected to the human serum albumin in series by a connecting peptide. An amino terminal and/or a carboxyl terminal of the insulin secretion promoter are connected to a carboxyl terminal and/or an amino terminal of the human serum albumin by a connecting peptide. The number of the amino acid sequences for coding the connecting peptides is equal to the number of the amino acid sequences for coding the insulin secretion promoter. The recombinant insulin secretion promoter fusion protein has the advantages of good drug effects, long half life, simpleness, high efficiency, safety and good application prospect.
Participants will be asked to undergo three brain-imaging scans throughout the course of the study. Once they are deemed eligible for participation based on two assessment visits, they will be scheduled for their baseline test day. On this they, they will be asked to under a series of cognitive tests following by a brain-imaging scan. They will then take the first dose of either the LDX or placebo, wait for 3 hours and then undergo another brain-imaging scan to assess acute changes to memory/cognition due to the study drug. They will then come in for three 30-minute check-in visits during weeks 2, 4 and 6 on the study drug. They will be asked to undergo a final scan and series of cognitive tasks during weeks 8-10 on the study drug. They will then be discharged from active study participation. All participants, regardless of randomization, will be offered a consultation with the study MD and optional prescription for 4-weeks of treatment with LDX.
PURPOSE:A polymer, prepared by reacting a polymer consisting of specific constituent units with a specific cytotoxic substance, and reacting the resultant polymer with a hydroxyl group-containing water-soluble low-molecular compound containing amino and hydroxyl groups, and having the joined cytotoxic substance, e.g. a carcinostatic agent. CONSTITUTION:A polymer obtained by reacting a polymer consisting of constituent units of formulaI[Z is H or monovalent cation; (m) is an integer 1-4], e.g. sodium poly-L-glutamate, with a cytotoxic substance, having amino or imino groups in the molecule, e.g. 1-[5'-(2-aminoethylphosphoryl)-beta-D-arabinofuranosyl]cytosine, in the presence of a condensing agent is reacted with a water-soluble low-molecular compound, e.g. 2-hydroxyethylamine, having one primary or secondary amino group and one or more hydroxyl groups in the molecule to give the aimed polymer having 60mol% or more total of constituent units of formulaI, II (X is reaction residue of the water-soluble low molecular compound) and formula III (Y is the reaction residue of the cytotoxic substance).
Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, the signals that initiate these events remain poorly understood. The inventors identify the nuclear alarmin interleukin (IL)-33 as an initiation factor of tissue injury and also as a major amplification factor of the innate immune response triggered by experimental kidney ischemia-reperfusion in mice. In mice lacking IL-33, IRI is reduced, as attested by early decreased tubular cell injury, and by subsequent decreased infiltration of IFN-γ/IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IL-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ.
Hoarseness due to vocal fold paresis (VFP) has a multitude of etiologies including systemic lupus erythematosus (SLE). During a clinical evaluation of a 58-year-old woman with long-standing hoarseness, an incidental finding of thyroid nodules was found to have VFP. Direct laryngoscopy and vocal fold biopsy confirmed the source was an inflammatory process involving the cricoarytenoid joint of the right hemilarynx. A presumptive diagnosis of SLE was made 3 years before meeting the clinical criteria of overt SLE. The VFP debut of SLE is extremely rare, and a literature review includes a handful of case reports (4 of a total of 37) since 1959. Only partial recovery of laryngeal function using glucocorticoids and Plaquenil was accomplished in the current case.
It was a control period. Participants were asked to continue their routine activities for 4 weeks.
OBJECTIVE: Retrograde open mesenteric stenting (ROMS) is an alternative to mesenteric bypass in patients with acute mesenteric ischemia (AMI) with variable reported 30-day mortality rates. Large studies evaluating patient outcomes following ROMS are scarce. Our study aims to assess the results of this approach among patients presenting with AMI.
METHODS: We reviewed all the patients with AMI who were treated with ROMS (2011-2022). Patient demographics, presentation, operative details, and outcomes were analyzed. Primary end points were in-hospital, 30-day, and 1-year mortality. Kaplan-Meier estimate for 1-year mortality and primary patency loss were generated. Secondary end points included postoperative 30-day complications.
RESULTS: Between 2011 and 2022, ROMS was attempted on a total of 42 patients. The median age was 70 ± 15 years and the majority of patients were female. Pain out of proportion to the physical examination was the most common presenting symptom (n = 18, 42.9%) followed by peritonitis (n = 14, 33.4%). All patients underwent preoperative intravenous contrast computed tomography imaging. In situ thrombosis was identified as the etiology of AMI in 36 patients (85.7%). Technical success was achieved in 40 patients (95.2%). Conventional, non-hybrid operating rooms were used for the majority of cases. Revascularization of all 40 patients involved angioplasty and stenting of superior mesenteric artery. A single stent was placed in 35 patients (87.5%) and the reminder had more than one stent. Eighty percent of patients required bowel resection. A second-look laparotomy was required in 34 patients (85.0%). The mean operative time, including both the general surgery and vascular surgery portions of the index procedure, was 192 ± 57 minutes. Sepsis was the most common complication observed within 30 days, occurring in 8 patients (20.0%). In terms of mortality, 13 patients (32.5%) died during their index hospitalization, and 9 died (22.5%) within 30 days. On Kaplan-Meier analysis, the 1-year overall patient survival rate was 58.6%, and the primary patency rate for stents was 51.4%.
CONCLUSIONS: ROMS has an excellent technical success rate in management of AMI with lower than traditionally reported mortality rates for AMI. The dual benefits of rapid revascularization and bowel evaluation should make this surgical modality an alternative approach for treatment of AMI.
BACKGROUND: Brazil has a large public transplant program, but it remains unclear if the kidney waitlist criteria effectively allocate organs. This study aimed to investigate whether gender, ethnicity, clinical characteristics, and Brazilian regions affect the chance of deceased donor kidney transplant (DDKT).
METHODS: We conducted a retrospective cohort study using the National Transplant System/Brazil database, which included all patients on the kidney transplant waitlist from January 2012 to December 2022, followed until May 2023. The primary outcome assessed was the chance of DDKT, measured using subdistribution hazard and cause-specific hazard models (subdistribution hazard ratio [sHR]).
RESULTS: We analyzed 118 617 waitlisted patients over a 10-year study period. Male patients had an sHR of 1.07 ([95% CI: 1.05-1.10], p < 0.001), indicating a higher chance of DDTK. Patients of mixed race and Yellow/Indigenous ethnicity had lower rates of receiving a transplant compared to Caucasian patients, with sHR of 0.97 (95% CI: 0.95-1) and 0.89 (95% CI: 0.95-1), respectively. Patients from the South region had the highest chance of DDKT, followed by those from the Midwest and Northeast, compared to patients from the Southeast, with sHR of 2.53 (95% CI: 2.47-2.61), 1.21 (95% CI: 1.16-1.27), and 1.10 (95% CI: 1.07-1.13), respectively. The North region had the lowest chance of DDTK, sHR of 0.29 (95% CI: 0.27-0.31).
CONCLUSION: We found that women and racial minorities faced disadvantages in kidney transplantation. Additionally, we observed regional disparities, with the North region having the lowest chance of DDKT and longer times on dialysis before being waitlisted. In contrast, patients in the South regions had a chance of DDKT and shorter times on dialysis before being waitlisted. It is urgent to implement approaches to enhance transplant capacity in the North region and address race and gender disparities in transplantation.
The invention belongs to the technical field of biological pharmacy, and provides a recombinant hypoglycemic polypeptide, a preparation method and application thereof. The recombinant hypoglycemic polypeptides NSTI and SSTI have the following amino acid sequences (1) and (2): (1) contains an amino acid sequence shown as SEQ ID No. 1; (2) The polypeptide has 75% homology with the amino acid sequence in the (1) and has the function of the amino acid sequence in the (1). Has the inhibiting activity of alpha-glucosidase and the inhibiting rate of the alpha-glucosidase is higher than that of acarbose. The alpha-glucosidase in the intestinal tract can be inhibited by being prepared into capsule oral medicines or hypoglycemic foods so as to achieve the hypoglycemic effect. Simple preparation, low cost and easy operation and implementation, thereby having very wide application prospect.
Gonioscopy-assisted transluminal trabeculotomy (GATT) is a promising cost-effective minimally invasive glaucoma surgery (MIGS). The main advantage is safety with regards to low risk for hypotony and its related complications. However, the Schlemm's canal (SC) based procedures have a different set of complications, the most common being hyphema and transient intraocular pressure spike. The other rare complications being, the false passage of the suture by traversing the external wall of the SC into the suprachoroidal space or posterior chamber or breaching the internal wall of the SC into the anterior chamber. Although these complications are rare, knowledge about them is important not only for early identification but for prevention and management if they occur. Through this case report, we describe a rare complication where the suture had traversed through a dilated episcleral vein during GATT. To our knowledge, there has been no prior report of such a complication.